Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial.

MLA

Zhou, Xingyu, et al. “Pre-Marketing Immunogenicity and Safety of a Lyophilized Purified Human Diploid Cell Rabies Vaccine Produced from Microcarrier Cultures: A Randomized Clinical Trial.” Human Vaccines & Immunotherapeutics, vol. 15, no. 4, Apr. 2019, pp. 828–33. EBSCOhost, https://doi.org/10.1080/21645515.2018.1549450.

APA

Zhou, X., Wu, X., Cai, Y., Cao, S., Zhu, X., Lv, Q., Chen, H., Shi, L., Li, J., Wang, X., Li, Y., & Zhou, R. (2019). Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial. Human Vaccines & Immunotherapeutics, 15(4), 828–833. https://doi.org/10.1080/21645515.2018.1549450

Chicago

Zhou, Xingyu, Xiaohong Wu, Yong Cai, Shouchun Cao, Xiaoping Zhu, Qiang Lv, Huaigong Chen, et al. 2019. “Pre-Marketing Immunogenicity and Safety of a Lyophilized Purified Human Diploid Cell Rabies Vaccine Produced from Microcarrier Cultures: A Randomized Clinical Trial.” Human Vaccines & Immunotherapeutics 15 (4): 828–33. doi:10.1080/21645515.2018.1549450.